Qishenyiqi Dripping Pill for Coronary Microvascular Disease

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Nov 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Qishenyiqi for people who have a condition known as coronary microvascular disease, which can cause chest pain due to problems in the small blood vessels of the heart. The researchers want to see how effective and safe this treatment is over a one-year period, looking specifically at how well blood flows in the heart and whether it helps prevent serious heart-related events.

To participate in this study, patients should have frequent chest pain, either with exercise or at rest, and their heart arteries should be mostly normal or only slightly blocked. However, those who have had a heart attack, certain heart surgeries, or other serious heart conditions, as well as pregnant or nursing women, will not be eligible. Participants will have regular check-ups to monitor their health and the effects of the treatment during the study. This trial is currently recruiting patients of all genders, aged between 14 and 27 years.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks;
• • Coronary normal or stenosis \< 20%;
• • Ischemic depression in ST segment during resting or exercise;
• • Blood flow reserve (CFR) of the anterior descending coronary artery \< 2.0;
• • Subjects or their guardians agreed to participate in this study.
• Exclusion Criteria:
• • Previous myocardial infarction or PCI or CABG treatment;
• • A history of heart failure;
• • Severe arrhythmia;
• • Refractory hypertension or hypertension accompanied by left ventricular wall thickness \> 12 mm;
• • Familial hypercholesterolemia;
• • Takayasu arteritis, Kawasaki disease or coronary artery malformation;
• • Pregnant or nursing, or having the intention to give birth within one year;
• • Hepatic or renal dysfunction;
• • Allergic to contrast agents or traditional Chinese medicines;
• • Patients who participated in clinical research of other drugs within 3 months before being selected.